Comparison

ALNYLAM PHARMACEUTICALS, INC. (ALNY) vs Moderna, Inc. (MRNA)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

ALNY

ALNYLAM PHARMACEUTICALS, INC.

Biotechnology

Revenue, FY25: $3.71B
Net income: $314M
Operating cash flow: $524M
Free cash flow: $465M
Net margin: 8.45%
Operating margin: 13.51%
Gross margin: 81.77%

MRNA

Moderna, Inc.

Biotechnology

Revenue, FY25: $1.94B
Net income: −$2.82B
Operating cash flow: −$1.87B
Free cash flow: −$2.07B
Net margin: −145.16%
Operating margin: −158.13%
Gross margin: 55.35%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	ALNY	MRNA
Revenue growth, latest filed year	+65.19%	−39.93%
Piotroski F-score	5 of 8	3 of 9
P/E against its own history	-	-

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

ALNY

FDA approval
Reimbursement
Data privacy
Litigation
Tax
Product recalls

And 15 more.

MRNA

FDA approval
Litigation
Data privacy
Pandemic
Reimbursement
Product recalls

And 15 more.

Tracked managers holding both

Baillie Gifford Baillie Gifford & Co 0.67% · 1.16%

Updated Sep 1, 2026 · the newer of the two companies' filings